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ABSTRACT
Introduction: In recent years, an unprecedented
emphasis has been given to the control of neglected
tropical diseases, including soil-transmitted helminths
(STHs). The mainstay of STH control is school-based
deworming (SBD), but mathematical modelling has
shown that in all but very low transmission settings,
SBD is unlikely to interrupt transmission, and that new
treatment strategies are required. This study seeks to
answer the question: is it possible to interrupt the
transmission of STH, and, if so, what is the most cost-
effective treatment strategy and delivery system to
achieve this goal?
Methods and analysis: Two cluster randomised
trials are being implemented in contrasting settings in
Kenya. The interventions are annual mass anthelmintic
treatment delivered to preschool- and school-aged
children, as part of a national SBD programme, or to
entire communities, delivered by community health
workers. Allocation to study group is by cluster, using
predefined units used in public health provision—
termed community units (CUs). CUs are randomised to
one of three groups: receiving either (1) annual SBD;
(2) annual community-based deworming (CBD);
or (3) biannual CBD. The primary outcome
measure is the prevalence of hookworm infection,
assessed by four cross-sectional surveys. Secondary
outcomes are prevalence of Ascaris lumbricoides and
Trichuris trichiura, intensity of species infections and
treatment coverage. Costs and cost-effectiveness will
be evaluated. Among a random subsample of
participants, worm burden and proportion of
unfertilised eggs will be assessed longitudinally.
A nested process evaluation, using semistructured
interviews, focus group discussions and a
stakeholder analysis, will investigate the
community acceptability, feasibility and scale-up of
each delivery system.
Ethics and dissemination: Study protocols have
been reviewed and approved by the ethics committees
of the Kenya Medical Research Institute and National
Ethics Review Committee, and London School of
Hygiene and Tropical Medicine. The study has a
dedicated web site.
Trial registration number: NCT02397772.
INTRODUCTION
Neglected tropical diseases (NTDs) are a
cluster of tropical diseases that affect more
than one billion people worldwide, mainly
Strengths and limitations of this study
▪ The study has a strong design incorporating
random allocation, blinding of assessors to the
primary outcome, and builds on and will, subse-
quently, refine mathematical modelling.
▪ The interventions include alternative treatment
strategies using two different delivery systems,
and are well-established, of long duration
(24 months) and nested within an ongoing
national control programme.
▪ The study includes cost-effectiveness analysis
and analysis of community acceptability, feasibil-
ity and scale-up of each delivery system.
▪ A limitation of the study is its reliance on existing
health structures to implement the intervention.
▪ The study will contribute to evidence regarding
the cost-effectiveness of soil-transmitted hel-
minth control and thereby inform national and
global policy.
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among poor populations living at the periphery of
health systems.1 NTDs can cause disability, disﬁgure-
ment, undernutrition and cognitive impairment, yet
many NTDs can be easily controlled by periodic mass
treatment using safe and broad spectrum drugs. Global
efforts to control NTDs reached a turning point in 2012,
when WHO launched its NTD Roadmap,1 and partners
met in London, and pledged to work together to
control and eliminate 10 NTDs by 2020.2 As part of this
commitment, pharmaceutical companies pledged to
donate the drugs required for mass treatment pro-
grammes and the challenge now is to support countries
in developing sustainable systems to distribute donated
medicines.
According to the 2010 Global Burden of Disease
study,2 the soil-transmitted helminths (STHs) spp Ascaris
lumbricoides, Trichuris trichiura and hookworm, contribute
the greatest disease burden among the NTDs, causing
an estimated 4.98 million years lived with disability each
year.3 Fortunately, much of this burden can be readily
averted by periodic, population-based chemotherapy
(also known as deworming). The WHO identiﬁes three
priority groups for deworming: school-age children,
preschool-age children and women of childbearing age,4
as they typically harbour chronic and intense infections
at a time when they are undergoing physical and/or cog-
nitive development. An effective mechanism to reach
school-age children is provided by school-based deworm-
ing programmes, which have been shown to cost-
effectively reduce their STH-related morbidity.5 6 In
2013, some 237 million school-age children—equivalent
to 39% of the global at-risk school-aged population—
beneﬁtted from STH treatment.7 However, if the 2020
target of treating 75% of school-age children is to be
reached, there needs to be a concerted effort to scale-up
deworming. Responding to this need, a new consortium
was established in Paris in 2014, to assist countries to
develop mechanisms for addressing STH among
Figure 1 Summary of study
design.
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preschool-age and school-age children.8 Partners at the
Paris meeting also committed support for evaluating the
potential of interrupting the transmission of STHs using
new tools and strategies. Recent analyses based on math-
ematical models of parasite transmission and the impact
of treatment have suggested that the transmission of
STHs can be interrupted (a breakpoint in transmission
is crossed where parasite elimination is achieved) if treat-
ment is expanded to adults and provided more fre-
quently.9–11 While such models can provide new insights,
there is an obvious need to test the predictions of the
impact and cost-effectiveness of alternative treatment
strategies through rigorous ﬁeld studies.
If there is to be a move towards broadening the range
of age groups targeted by STH treatment programmes,
then it is necessary to identify suitable delivery systems.
Possibly the longest running community-based NTD
control programme that treats across all age groups is
the African Programme for Onchocerciasis Control,
which has helped countries create a community-directed
treatment strategy by involving community-directed drug
distributors and extending and strengthening health
systems.12–14 A community-based approach is also
employed by national lymphatic ﬁlariasis (LF) control
programmes, whereby community drug distributors or
community health workers (CHWs) provide community-
wide delivery of albendazole plus ivermectin (or
diethylcarbamazine in areas not endemic for onchocer-
ciasis) to entire populations aged 2 years and above.15
Although CHWs are increasingly used to promote
healthy behaviours and deliver basic health services,
especially in poor and underserved communities,16 17
the beneﬁts of using a CHW-based approach for STH
control is poorly understood at present.
This paper describes two cluster randomised trials in
Kenya that seek to provide new evidence on the impact
and cost-effectiveness of alternative treatment strategies
and delivery systems in reducing the transmission of
STHs. Such evidence will help establish proof-of-concept
of the possibility of interrupting STH transmission and
would likely be of value to policymakers in
STH-endemic countries, and partners and funders sup-
porting STH control.
Aims and objectives
The overall aim of the trials is to evaluate the impact
and cost-effectiveness of school-based versus community-
based deworming on measures of STH transmission in
Kenya. Speciﬁcally, we will test the hypothesis that treat-
ment needs to be provided to a broad range of ages
and/or at more frequent intervals than 1 year in order
to interrupt the transmission of STH. The study also
includes process and economic evaluations to assess the
feasibility and implementation of the alternative
Figure 2 Map showing location
of study sites and community
units.
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treatment strategies and delivery systems, which will
guide scale-up of the programmes in Kenya and other
settings in Africa. The more detailed study objectives
are:
1. To quantify the impact of school-based versus
community-based mass treatment (treatment strat-
egies and delivery systems) at annual and biannual
intervals (treatment strategies) in reducing the trans-
mission of STH spp, hookworm, A. lumbricoides and
T. trichiura.
2. To evaluate the costs and cost-effectiveness of alterna-
tive STH treatment strategies and delivery systems in
reducing transmission.
3. To assess the extent to which community-based treat-
ment programmes for STH are acceptable to the
community, which are feasible, given the health
system capacity, and can be easily scaled-up across
Kenya and elsewhere.
METHODS AND ANALYSIS
Reporting of the study protocol has been veriﬁed in
accordance with the SPIRIT (Standard Protocol Items
for Randomised Trials) recommendations.
Overall study design
Two paired community cluster randomised trials in dif-
ferent settings in Kenya will evaluate the impact and
cost-effectiveness of annual school-based deworming,
annual community-based deworming and biannual
community-based deworming. The trials are designed as
cluster randomised, open-label trials with three study
groups. The primary outcome is the prevalence of hook-
worm. This outcome was selected because it is the STH
spp that contributes most to morbidity, is responsible for
the most DALYs lost due to STH3 and is the species
most difﬁcult to control using school-based deworming
alone.9 Allocation to study group is by cluster, using pre-
deﬁned units used in public health provision—termed
community units (CUs). The three study groups are:
1. Control group: Annual school-based deworming.
Preschool and school children (typically aged
2–14 years) will receive a single dose of albendazole
(400 mg) from trained school teachers, as part of the
ongoing national school-based deworming
programme.
2. Expanded age range group: Standard school-based
deworming supplemented by annual community-
based deworming (2–99 years). All household
members who are not enrolled in school will receive
a single dose of albendazole (400 mg) from trained
CHWs—known in Kenya as community health volun-
teers (CHVs).
3. Expanded age range and frequency group: Annual school-
based deworming supplemented by community-based
deworming (2–99 years), followed by an additional
community-based deworming 6 months later. All
household members who are not enrolled in school
will receive a single dose of albendazole (400 mg)
from trained CHVs.
Mathematical models suggest that there is little differ-
ence in the impact of annual or biannual school-based
Table 1 Epidemiological and socioeconomic characteristics in the two study areas
Bungoma Kwale County National average Source
Helminth infections
STHs combined (%) 49.3 33.6 32.4* 27
Hookworm (%) 44.3 27.7 15.6* 27
Ascaris lumbricoides (%) 28.2 0.8 18.0* 27
Trichuris trichiura (%) 0.8 8.9 6.6* 27
Schistosoma haematobium (%) non-endemic 17.5 14.8* 27
Wuchereria bancrofti (%) non-endemic endemic endemic in 6 of 47 counties 28
Socioeconomic conditions
Poverty rate (%)† 52.2 72.9 46.6 29
Access to water and sanitation
Improved drinking water (%) 72.1 51.2 55.1 30
Improved sanitation (%) 71.2 34.4 64.9 30
School system
Primary school attendance (%)‡ 94.6 87.2 85.6 30
Literacy rate (%) 60.5 66.5 66.4 31
Health system
Full immunisation coverage (%)§ 84.4 77.5 83.0 32
Doctors (per 100 000 people) 4 1 7 32
Nurses (per 100 000 people) 37 37 49 32
*Among schools included in the monitoring and evaluation of the national school-based deworming programme.
†Percentage of population living below the Kenya poverty line (Ksh 1562 per person per month in rural areas and Ksh 2913 in urban areas).
‡Percentage of the official primary school-age population that attends primary school.
§Percentage of population that completed 3+ doses of diphtheria, pertussis and tetanus vaccination.
STH, soil-transmitted helminth.
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deworming, given the expected prevalence in our study
sites,10 18 and therefore we did not include biannual
school-based deworming as a study group. In other set-
tings where A. lumbricoides is more common and hook-
worm is absent, biannual treatment may be desirable
due to the relatively higher levels of infection in school-
age children compared to adults.
The primary outcome, the prevalence of hookworm
infection, will be measured through cross-sectional para-
sitological surveys conducted at baseline and at 12, 24
and 30 months follow-up. The timing of the ﬁnal
follow-up survey takes into account differences in time
since treatment of the annual and biannual treatment
groups at 24 months. The overall study design is sum-
marised in ﬁgure 1. A subsample of individuals from two
CUs in each of the study groups will be followed longitu-
dinally for two and half years, in order to better under-
stand the transmission dynamics of STHs and to
estimate key parameters for the mathematical models of
transmission dynamics and treatment impact. A nested
process evaluation, using semi-structured interviews,
focus group discussions (FGDs) and a stakeholder ana-
lysis, will investigate the community acceptability, feasibil-
ity, given the local and regional health system structures
and processes, and scale-up of the interventions.
Interventions
All study groups will receive treatment with albendazole
(400 mg), which is highly efﬁcacious against A. lumbri-
coides and hookworm, but has lower efﬁcacy against
T. trichiura.19 What differs between the three study
groups is the age range of populations that receive treat-
ment and the frequency at which treatment is provided.
School-based deworming will be implemented in all
communities as part of the national school-based
deworming programme (NSBDP). Launched jointly in
2009 by the Ministry of Education, Science and
Technology (MoEST), and the Ministry of Health
(MoH), and funded by the Children’s Investment Fund
Foundation, the programme’s goal is to eliminate STHs
and schistosomiasis as a national public health problem.
A single 400 mg dose of albendazole is provided
Figure 3 The relationship between baseline prevalence of hookworm infection (proportion of all community members found to
be infected) and predicted impact following 2 years of treatment for each proposed treatment strategy. Based on a mathematical
model of transmission dynamics, assuming 80% treatment coverage of school-based deworming and 70% of community-based
treatment. Biannual school-based treatment did not differ significantly from annual school-based treatment and therefore is not
shown. Sensitivity of diagnosis is assumed to be 63%.
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annually by trained teachers on designated deworming
days. The programme targets all children in at-risk sub-
counties enrolled in public and private primary schools
and early childhood development centres (kindergar-
tens).20 Non-enrolled school-age children are also
encouraged to come to school for treatment on
deworming day. The NSBDP makes use of a cascade
model whereby trainings, materials, drugs and funds are
channelled from the national level through the county
to the school level, involving ofﬁcials from MoEST and
MoH throughout the cascade. The emphasis is on
MoEST for delivery and MoH for supervision. Treatment
coverage data and remaining drugs are returned along
the reverse cascade. No adaptations shall be made to the
NSBDP for the study other than modiﬁcation of the
treatment and coverage forms to strengthen the data
capture on treatment at the individual level, and to val-
idate treatment coverage.
Community-based deworming will be provided by
CHWs, called CHVs in Kenya. CHVs already promote
care seeking and compliance to antiretroviral and tuber-
culosis treatment, and mobilise populations during
national health campaigns, as part of the national com-
munity health strategy.21 This strategy also includes the
establishment of CUs, which each serve approximately
1000 households or 5000 people, with a single CHV pro-
viding service to approximately 100 households. For
every 25 CHVs, there is one Community Health
Extension Worker (CHEW) who is a Ministry of Health
employee with training in public health or nursing. This
CHEW provides supervision and technical support to
the CHVs. The community health strategy was revised in
2010, with new guidance on the contents of CHV kits to
include basic drugs such as paracetamol, albendazole
and tetracycline.22 The community-based deworming in
the present trials will provide door-to-door treatment,
drawing on the previous experience of the National
Programme for Elimination of LF, which, to date, has
implemented four rounds of mass treatment (2002,
2005, 2008 and 2011), but with variable levels of treat-
ment coverage.23
Setting
The study will be conducted in two settings of Kenya
that have contrasting epidemiological and programmatic
characteristics: Kwale County on the south Kenyan coast
and Bungoma County in western Kenya (ﬁgure 2). Key
epidemiological and sociodemographic characteristics of
the two study areas are summarised in table 1.
Historically, STH infections have been highly prevalent
in both regions but recent control efforts have reduced
levels of infection. A. lumbricoides is more common in
western Kenya, whereas hookworm predominates on the
coast.20 T. trichiura is present in both settings, but at low
levels. In Kwale County, in addition to STHs, there is
focal transmission of Schistosoma haemotobium, and LF is
endemic.24–26 In relation to sociodemographic
characteristics, Kwale County is among the poorest in
Kenya, with low levels of access to water and sanitation,
and minimal primary school enrolment, while Bungoma
lies close to national averages for these factors.
Randomisation
Allocation to study group will be by cluster, using CUs.
In areas where there are no formal CUs in existence, we
worked with the public health ofﬁcers and CHEWs to
delineate CUs in order to ensure that every village and
government is assigned to a CU. Randomisation was
stratiﬁed by the prevalence of hookworm (below and
above 20% prevalence, as determined in the baseline
survey), and subcounty and size (below and above 840
households), in order to reduce the likelihood of
chance imbalances. Randomisation took place at public
ceremonies. The randomisation sequence generation
was undertaken by an independent statistician using
computerised random number generation. Sealed envel-
opes containing CU identiﬁcation were placed in pre-
stratiﬁed ballot boxes, with delegates invited to select
envelopes from the boxes and directed to put the
selected envelope in a box labelled A, B or C (corre-
sponding to the three study groups trial) according to
the pregenerated randomisation sequence for that
stratum. In each CU, 225 households are randomly
selected and one randomly selected household member
is recruited into the cross-sectional surveys.
Owing to the nature of the interventions, participants
are not blinded to their group randomisation. However,
the identity of the study groups remains hidden until
the completion of community sensitisation and random-
isation to eliminate participation bias. In addition, the
laboratory technicians conducting stool examinations
and the statistician responsible for analysis are blinded
to the group assignment.
Contamination between clusters may occur when
people from one cluster receive treatment implemented
in another cluster or have lower exposure to STH infec-
tion due to lower transmission in another cluster. Our
use of CUs, which comprised groups of villages rather
than single villages, helps reduce the possibility of con-
tamination. CUs, including CUs located in urban and
periurban areas, which generally are not comprised of
distinct groups of villages, were excluded.
Sensitisation and recruitment
Key stakeholders and policymakers have been involved
in the study and its design from conceptualisation.
Meetings have been held with the MoH and MoEST in
Nairobi, and at each study site, where key stakeholders
were sensitised about the study objectives, intervention
and evaluation procedures, and requested to provide
input. Community meetings were held to describe the
purpose of the study, the interventions, the evaluation
procedures to be followed, and the risks and beneﬁts of
participation. Individuals had the opportunity to ask
questions. Consent for the intervention was provided at
the community level with the option for individuals to
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opt-out either from receiving treatment or study
assessments.
Consent for the baseline and follow-up cross-sectional
surveys is obtained at the individual level. Field staff enu-
merate all households through coordination with the
chiefs and village elders. Subsequently, households
selected for inclusion into the study are visited by ﬁeld
staff. In each household visited, written informed
consent to conduct the household-level questionnaire is
sought from the household head. Following this, a
random function programmed in a smartphone selects
the individual within the household who will provide a
stool sample and answer further individual-level ques-
tions. Individual-level informed consent is sought from
selected individuals (either for themselves or their chil-
dren) and written assent sought from children over
13 years of age. Inclusion criteria for the selection of
individuals include: (1) resident for at least 12 months,
(2) willingness of adult aged 18 years and above or
parent/guardian to provide written informed consent,
and (3) provision of written assent to participate from
children aged between 13 and 17 years. Exclusion cri-
teria include: (1) recent (<12 months) resident or
visitor to household at time of household visit, (2)
refusal of informed consent and (3) refusal to assent by
children aged 13–17 years.
Outcomes
The primary outcome is the prevalence of hookworm
(Necator americanus or Ancylostoma duodenale) infection
among all sampled individuals during 30 months of
follow-up. Owing to ethical considerations of treating
those found infected during surveys, new populations of
individuals will be selected for each cross-sectional
survey (baseline, 12, 24 and 30 months). All participants
are asked to provide a stool sample, which is examined
in duplicate using the Kato-Katz method. Individuals
found infected are revisited by the study team and
treated with albendazole. In a random subset of indivi-
duals, additional conﬁrmatory diagnosis of infection is
based on real-time PCR, which also allows the differenti-
ation between hookworm spp.33 34
The main secondary outcomes include:
▸ Prevalence of A. lumbricoides and T. trichiura, based on
expert microscopy and, in a random subsample, on
real-time PCR.
▸ Intensity of infection for each STH spp, based on
quantitative egg counts.
▸ Treatment coverage, measured using both routine
data, and data collected during household visits to
track treatment coverage and compliance.
Survey procedures
At each house visited, household heads are interviewed
to collect a household census and information on
household characteristics and ownership of key assets
during household visits. Data on household water, sanita-
tion and hygiene (WASH) conditions and school WASH
conditions are collected using structured observations
and questionnaires, employing tools piloted and exten-
sively used in Kenya.35 36
Teachers and CHVs will be provided with treatment
registers and asked to provide a full record of all indivi-
duals who have received treatment. To augment these
data, population-based coverage surveys using multistage
clustering sampling37 will be carried out among a
random subsample of communities.
In each cross-sectional survey, a randomly individual
selected is asked to provide a stool sample, which is
transported to a nearby health facility laboratory and
examined in duplicate within 1 h of processing using the
Kato-Katz method. Duplicate slides are read by inde-
pendent microscopists. A 10% quality control check is
performed by a supervisor. Aliquots of randomly
selected stool samples are preserved in ethanol for con-
ﬁrmatory real-time PCR diagnosis.33 34 In addition, stool
samples will be stored for future molecular analysis,
including the detection of potential drug resistance
alleles,35 38 and genome sequence analysis to investigate
the genetic structure of helminth populations.39
All members of the study teams have been appropri-
ately trained in the study objectives and procedures.
Standard operating procedures have been developed,
ﬁeld-tested and revised, and are used to guide all ﬁeld
activities. Supervisors make regular visits to the ﬁeld to
monitor ﬁeldwork.
Longitudinal studies
In six CUs (one with a medium (20–49%) and one high
(>50%) prevalence of hookworm in each study group),
individuals will be followed longitudinally to help quan-
tify the transmission dynamics of the parasites and
re-parameterise mathematical models of transmission
dynamics. An age-stratiﬁed random sample of 200 indivi-
duals will be chosen and asked to provide complete
stool samples for a period of 5 days immediately follow-
ing treatment. The collected stool will be transported to
an off-site sorting facility, A. lumbricoides and hookworm
will be manually separated from the stool, and the
number and sex or worms recorded for each individual.
The proportion of unfertilised eggs will also be deter-
mined for A. lumbricoides, given the importance of this
measure as a determinant of how effective a given treat-
ment programme is in driving transmission to extinction
by crossing the transmission threshold where insufﬁcient
mating occurs to sustain transmission.40 Selected indivi-
duals will be revisited at 1, 3, 6, 9 and 12 months post-
treatment and asked to provide a stool sample, which
will be examined for the presence of STH eggs in dupli-
cate using the Kato-Katz method.
We will also conduct household visits to assess the
extent of non-compliance to treatment and factors asso-
ciated with non-compliance.37 Adverse events will be
monitored in these cohorts during household visits.
Reports of severe adverse events that are classiﬁed as at
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least possibility related to the study drugs will be
reported to the ethics committee.
Sample size calculation
Sample size calculations are based on the principles of
cluster randomised trials.41 Analysis of survey data col-
lected as part of the ongoing monitoring and evaluation
of the NSBDP suggests that the prevalence of hook-
worm, the primary outcome, varies between 5% and
10%, with an intracluster correlation coefﬁcient (ICC)
of 0.125.2 The assumed difference between the study
groups in the prevalence of hookworm after 30 months
is based on mathematical modelling of the predicted
impact of different treatment strategies,11 12 and is pre-
sented in ﬁgure 3 for different degrees of prevalence of
infection at baseline. The ﬁgure also presents the
number of clusters required to detect the smallest pre-
dicted difference between school-based treatment and
two other arms with 80% power a 5% level of signiﬁ-
cance, an ICC of 0.125 and 225 participants per cluster.
Based on these calculations and taking into account
potential loss to follow-up of CUs (assumed to be 5%), a
conservative sample size of 40 clusters per group will be
used in both study areas.
Data management
Data are collected in the ﬁeld using Samsung GT7552
smartphones running android operating system V.4.2.
The questionnaires are programmed using Survey CTO
software (http://www.surveycto.com) and data are down-
loaded daily using secure Wi-Fi in the ﬁeld ofﬁce into a
web-based database. Backup of the database to a central
server is performed daily. Laboratory results are
recorded in laboratory books by technicians and double-
entered into a customised database and saved on a cen-
tralised server.
Data analysis
Primary analysis will be carried out on groups as rando-
mised (intention-to-treat). Results will be presented as
appropriate effects sizes with a measure of precision
(95% CIs). Clustering by CU will be included in all ana-
lyses. Our main analysis of the primary outcome, the
prevalence of hookworm, and other secondary out-
comes, will be based on cross-sectional analyses compar-
ing the outcome at 30 months follow-up between study
groups. Unadjusted and adjusted results will be pre-
sented for all analyses. Covariates in adjusted analyses
will be speciﬁed a priori and will include subcounty and
urban/rural classiﬁcation, household socioeconomic
status, and access to adequate water and sanitation. For
continuous outcomes, analyses will adjust for baseline by
inclusion of the cluster mean of the outcome in ques-
tion as a covariate in statistical models. For binary out-
comes (notably the primary outcome), no baseline
adjustment will be made because of issues relating to the
non-collapsibility of ORs.
Demographic and other baseline characteristics of
clusters will be compared to check for imbalances
between study groups. Tabulation of these measures will
be generated using the intention to treat data sets. No
signiﬁcance tests will be performed to investigate for dif-
ferences between groups at baseline. Where imbalances
are suspected, further exploratory adjusted analyses will
be carried out that include additional adjustment for
these factors. Formal statistical testing will be restricted
to comparison between the two community-based treat-
ment groups and the school-based treatment group
(control). A small number of secondary outcomes will
be prespeciﬁed for statistical testing along with the
primary outcome. No formal adjustment will be made
for multiple testing but the number of outcomes for-
mally tested will be restricted to fewer than 10 and the
results interpreted with due caution. This includes multi-
plicity associated with the two experimental arms. No
formal comparisons will be made between the two
experimental arms as the study has not been powered
for this analysis.
A small number of secondary subgroup analyses will
be speciﬁed in advance and will be carried out using
formal statistical tests for interactions. These will include
household poverty, remote households, frequent non-
compliers of treatment, non-enrolled children, and
households without access to adequate water and sanita-
tion. These analyses will help understand the impact het-
erogeneity of the interventions.
Process evaluation
A key study objective is to understand lessons for the
scale-up of community-based deworming in Kenya and
elsewhere in Africa. Therefore, a qualitative evaluation
will seek to identify and describe key assumptions and
conditions underlying the implementation, sustainability
and scaling-up of the different strategies and delivery
systems. The focus of the evaluation will centre on
whether CHVs can be utilised for the effective delivery
of chemotherapy for control of STH and what factors
inﬂuence the use of CHVs, including what type of incen-
tives, if any, should be given. Investigation will focus on:
(1) community acceptability, which will be assessed
during FGDs and in-depth interviews (IDIs); and (2)
feasibility, including a situation and stakeholder analysis
of the structural, organisational and management
factors that enhance or constrain effective implementa-
tion.42 A series of FGDs will be conducted with commu-
nity members, teachers, CHVs, CHEWs and local health
ofﬁcials, to better understand the acceptance and imple-
mentation of the interventions, using predeﬁned and
structured topic guides. FGDs will be stratiﬁed by loca-
tion and socioeconomic status, and speciﬁc efforts will
be made to reach groups that may be marginalised due
to their economic and sociocultural position. IDIs will
be carried out with a range of actors and opinion
leaders in order to understand the process and con-
straints of the different delivery systems. The number of
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IDIs will depend on when saturation is reached, but they
will include members of the county, and national health
and education teams.
FGDs and interviews will be digitally recorded, with
notes additionally taken, transcribed and translated.
Transcripts will be imported into NVivo (QSR
International, Doncaster, Australia), coded by two inde-
pendent coders, and analysed using content analysis to
identify emerging themes.43 Following descriptive ana-
lysis, patterns and linkages among views, experiences
and behaviours of the participants will be explored. The
collected data will provide important contextual infor-
mation and a basis for evaluating the generalisability of
the study ﬁndings. The work will beneﬁt from previous
qualitative evaluations by the research teams in the study
areas.44–47
Cost analysis
Cost data will be collected following an ingredients
approach, based on a semistructured questionnaire and
by consultation of the programme accounting system.
Data collection will be based on a standardised costing
framework, capturing ﬁxed and recurrent costs incurred
at school and community levels. The questionnaire will
include both cash and in-kind contributions, and will be
used to estimate ﬁnancial and economic costs of the
alternative treatment strategies (annual vs biannual
deworming) and delivery systems (through schools by
teachers and through door-to-door delivery by CHVs).
Financial costs capture actual expenditures in terms of
programme implementation, whereas economic costs
include opportunity costs of teachers, CHVs and other
stakeholders in delivering deworming. Opportunity costs
of the government staff and community members will be
calculated using local pay scales. Capital costs will be
annuitised over the useful life of equipment, vehicles
and other assets using a discount rate of 3%. Costs will
be assessed from a societal perspective. Analysis of costs
will be linked to volume of treatment in order to deter-
mine cost functions. The work will also present an ana-
lysis of the full cost of running national programmes in
Kenya. Itemised-costing and sensitivity analysis will
enable estimation of the costs of scaled-up implementa-
tion, and implementation in settings with different epi-
demiological and programmatic characteristics.
Mathematical modelling and cost-effectiveness analysis
The questions being addressed in the trial arose from
analyses of the predicted impact of mass treatment
based on mathematical models of the transmission
dynamics and control of STHs.9–11 48 The potential for
transmission of STHs and other helminths in a deﬁned
setting can be quantiﬁed by the value of the basic repro-
ductive number (R0), which is deﬁned as the average
number of offspring produced by one female worm that
survives to reproductive maturity. R0 can be stratiﬁed by
age (age-related exposure), and various environmental
and behavioural factors.49 In endemic communities,
mathematical models of helminths that are dioecious
have two stable points (no parasites and a stable
endemic equilibrium of parasite persistence), separated
by an unstable point—the so called ‘breakpoint’ in
transmission (a point at which R0 falls to just above but
close to unity (1) in value), below which continued treat-
ment can quickly drive the population to extinction. For
attempts at elimination, the goal of mass treatment is to
drive the parasite population below the ‘breakpoint’ by
treating sufﬁcient fractions of the target population.
Models of STH transmission provide insight into optimal
treatment strategies for achieving this breakpoint,9 10
and show that annual or biannual community-based
deworming can reduce overall prevalence and associated
intensity substantially. As an example, reaching the trans-
mission breakpoint can be achieved after 2 years given a
baseline prevalence of 10% or less (low transmission
setting) if coverage is high. The models also highlight
how the age-distribution of worm burden determines
the breadth of age groups that should be treated and
the importance of considering the species mix.
Data arising from the trials will be used to validate the
initial model predictions and to provide better estimates
of key epidemiological parameters for use in model pre-
dictions. Speciﬁcally, the study will produce better esti-
mates of the following parameters: density dependent
fecundity, parasite distributions in the various age group-
ings (estimates of the negative binomial aggregation par-
ameter k), age dependent exposure to infection, drug
efﬁcacy and treatment compliance. The models will be
ﬁtted with estimates of age-stratiﬁed patterns of reinfec-
tion and intensity of infection, as well as estimates of
treatment coverage using Monte Carlo Markov Chain
methods. Such model ﬁtting and parameter estimation
will allow examination of whether the observed and pre-
dicted impact is consistent. A stochastic model of STH
transmission is also under development to enable esti-
mates of variability around deterministic predictions
(such as time to crossing the breakpoint) to be made
taking account of the many heterogeneities involved in
parasite transmission.
The models will be used to explore the impact of the
different treatment strategies in a range of settings, with
different underlying intensity in levels of transmission
and treatment coverage, and the potential impact of
alterations (in coverage and frequency) to the treatment
strategies over time. The duration of treatment required
to cross the ‘breakpoint’ in transmission will also be
examined. Particular attention will be given to non-
compliers to treatment (both persistent and irregular)
in all study groups, and work will examine the impact on
overall transmission of poor adherence to treatment.
The cost data, detailed above, will be integrated into the
models for cost-effectiveness analysis. The incremental
costs per infection, heavy infection, anaemia case and dis-
ability adjusted life years averted will be estimated for the
two new strategies compared to the current situation with
annual school-based deworming. Sensitivity analysis will be
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undertaken to account for uncertainties in the analysis,
with attention given to the impact of non-compliance.
ETHICS AND DISSEMINATION
Ethical approval
The study has been approved by the Kenya Medical
Research Institute and National Ethics Review Committee
(SSC Number 2826) and the London School of Hygiene
and Tropical Medicine (LSHTM) Ethics Committee
(7177). Sponsorship and insurance is provided by the
LSHTM’s Clinical Trials Sub-Committee (QA615).
Informed consent
The study is intentionally embedded within the ongoing
NSBDP, which will continue to deliver deworming to all
schools in the study areas. At the time of household
visits, household members are asked to give their verbal
consent for their participation in the community-based
deworming. Written informed consent is obtained from
adults and parents or guardians of children, before
enrolment in the cross-sectional surveys and longitudinal
surveys. Written informed consent will also be sought
from individuals included in the qualitative evaluations,
including FGDs and in-depth interviews. Participants of
FGDs and interviews will be provided the options not to
be quoted in any reporting of ﬁndings. Study informa-
tion sheets are provided in English, Kiswahili, Mijikenda,
Luhya or Bukusu. Translated documents were veriﬁed
through back-translation into English. Written assent to
participate in the cross-sectional and longitudinal studies
is obtained from children aged 13 years and above.
Risks and beneﬁts of participating in the study are pre-
sented during community meetings and any issues
arising discussed. The risk of participating in the trial is
very low. The study drug, albendazole, is extremely safe
and no severe adverse events are expected.50 In the
unlikely situation of events occurring, these will be
reported to the study site investigator and the principal
will inform the ethics committee. Collection of stool
samples is a routine procedure and is considered not to
be a medical risk; there is the possibility of embarrass-
ment, which will be minimised by appropriate action.
All information will remain conﬁdential. Laboratory
specimens, reports, data collection, and process and
administrative forms will be identiﬁed by a coded
unique identiﬁer to maintain participant conﬁdentiality.
Access to collected data will initially be limited to ﬁeld-
workers at the point of data collection, and to the study
statistician and investigators during analysis. As indicated
below, data that are considered non-sensitive and do not
include identifying participant information will be made
publicly available once the main ﬁndings have been pub-
lished, subject to appropriate data sharing agreements.
Trial oversight
No data safety and monitoring board will be established
since the interventions are extremely safe and already
delivered to hundreds of millions of individuals each
year as part of national deworming programmes.
Instead, an independent Data Monitoring Committee
(DMC), consisting of a chair and three members, and
operating under a remit of a charter, has been estab-
lished to monitor data for quality and completeness.
The DMC will review, in strict conﬁdence, an interim
analysis of the 12-month data. The DMC will also review
and approve the ﬁnal data analysis plan.
Dissemination
The study has a dedicated web page, on the Global
Atlas of Helminth Infection (GAHI) website (http://
www.thiswormyworld.org/tumikia-project), where study
updates and ﬁnal results will be disseminated. Study
ﬁndings will also be disseminated through multiple and
innovative media, ensuring that research is presented in
ways that are most appropriate for the various stake-
holders identiﬁed during the stakeholder mapping. The
data collected in the study along with the study instru-
ments will be made publicly available following the pub-
lication of the main study ﬁndings, based on approved
data sharing agreements.
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